Denali Therapeutics Inc. Company Profile
NASDAQ: DNLIHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 7, 4:00 PM ET · Delayed 15 min
After hours: 19.16 0.00%
Denali Therapeutics at a glance
Denali Therapeutics Inc. (NASDAQ: DNLI) is a Biotechnology: Biological Products (No Diagnostic Substances) company in the Health Care sector headquartered in South San Francisco, CA. Denali Therapeutics is led by Dr. Ryan J. Watts Ph.D. and employs about 503 people. The company's shares have traded publicly since 2017.
At a market capitalization of $3.08 billion, it is considered a mid-cap company. Its SEC Central Index Key (CIK) is 0001714899, which identifies the company's filings on EDGAR.
Summary generated from market data by MetaCap's automated system. Methodology
What does Denali Therapeutics do?
Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutics to treat neurodegenerative and lysosomal storage diseases. The company develops Eclitasertib (SAR443122/DNL758) RIPK1 inhibitor program for peripheral inflammatory diseases; BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; TAK-594/DNL593 program for frontotemporal dementia-granulin; DNL126 program for MPS IIIA (Sanfilippo Syndrome A); and DNL310 Tividenofusp alfa, an enzyme replacement therapy program for MPS II (Hunter Syndrome). Its Enzyme TransportVehicle (TV) programs include DNL952 for the treatment of Pompe disease; DNL111 for Parkinson's and Gaucher diseases; and DNL622 for Hurler syndrome (MPS I). The company's OTV programs also comprise DNL628 targeting tau for Alzheimer's disease; and DNL422 targeting alpha synuclein for Parkinson's disease, as well as antibody TV program includes DNL921 targeting Abeta for treating Alzheimer's disease. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.
Business description based on the company's public filings.
Company information
- Legal name
- Denali Therapeutics Inc.
- Ticker
- NASDAQ: DNLI
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- CEO
- Dr. Ryan J. Watts Ph.D.
- Employees
- 503
- Headquarters
- 161 Oyster Point Boulevard, South San Francisco, CA, United States
- Phone
- 650 866 8547
- Website
- denalitherapeutics.com
- IPO year
- 2017
- Market cap
- $3.08B
- SEC CIK
- 0001714899
Companies similar to Denali Therapeutics
| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| TARSTarsus Pharmaceuticals Inc. | 73.61 | -0.67% | $3.44B | vs DNLI |
| BEAMBeam Therapeutics Inc. | 24.77 | -1.82% | $2.56B | vs DNLI |
| RXRXRecursion Pharmaceuticals Inc. Class A | 4.27 | -7.78% | $2.29B | vs DNLI |
| ADMAADMA Biologics Inc | 10.14 | -0.39% | $2.27B | vs DNLI |
| RLAYRelay Therapeutics Inc. | 17.95 | -4.22% | $3.93B | vs DNLI |
| BCRXBioCryst Pharmaceuticals Inc. | 8.40 | +5.66% | $2.15B | vs DNLI |
| ALVOAlvotech | 5.85 | -4.72% | $2.09B | vs DNLI |
| VCELVericel Corporation | 40.74 | +1.72% | $2.09B | vs DNLI |